- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01326104
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor (Re-MATCH)
Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor Adoptive T Cell Therapy During Recover From Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation
Immunotherapy is a specific approach to treating cancer that has shown promise in adult patients for the treatment of melanoma, malignant brain tumors, and other cancers. The study investigators will use the experience they have gained from these studies to try to improve the outcome for children affected by a recurrent brain tumor.
Approximately 35 patients with first recurrence of medulloblastoma (reMB)/supratentorial primitive neuroectodermal tumors (PNETs) will be treated with tumor-specific immune cells and dendritic cell vaccines to see what impact they have on the tumor.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Malignant brain tumors now represent the most frequent cause of cancer death in children. Despite aggressive and highly toxic multi-modality therapy including surgery, craniospinal radiation, and high-dose chemotherapy coupled with peripheral blood stem cell transplantation, almost half the children diagnosed with the most common malignant brain tumors, medulloblastoma (MB) and primitive neuroectodermal tumors (PNET), will still die from recurrent disease. Furthermore, survivors are often left with severe and lifelong treatment-associated cognitive and motor deficits. The development of more effective and tumor-specific therapies that will not add further toxicity to existing treatments is paramount in improving clinical outcomes for children affected by MB/PNETs. Immunotherapy targeting tumor-specific antigens expressed within brain tumors is a modality potentially capable of meeting this clear and urgent need.
Despite considerable advancements and promising clinical results observed in immunotherapy trials directed against adult malignant brain tumors, efforts in the immunologic treatment of pediatric brain tumors have been limited to relatively few notable studies. This is due, at least in part, to the often limited viable tumor tissue available for tumor cell-based vaccine preparations, and the lack of identification of consistently expressed tumor-specific antigens within these cancers.
The use of total tumor RNA (TTRNA)-loaded dendritic cells (DCs) was pioneered at Duke University, as a novel platform for inducing potent immunologic responses against the variety of uncharacterized and patient-specific antigens present within malignant tumor cells. Duke demonstrated that sufficient RNA for clinical vaccine preparations can be amplified with high fidelity using existing molecular technologies from as few as 500 isolated pediatric and adult brain tumor cells, thus allowing vaccine preparation from surgical biopsies and even microdissected archival tumor specimens.
Immunotherapy administered during recovery from chemotherapy may have tremendous advantages, as adoptive cellular therapy following lymphodepletive conditioning regimens has emerged as the most effective treatment strategy for advanced and refractory melanoma. Our hypothesis is that DC + ex vivo expanded Autologous Lymphocyte Transfer (xALT) therapy targeting recurrent MB/PNETs during recovery from myeloablative chemotherapy will be safe and will prolong survival in children and young adults with recurrent MB/PNETs.
In this study, the investigators will treat patients with first recurrence reMB/PNETs after completion of definitive radiation therapy with autologous tumor-specific T cell immunotherapy (TTRNA-xALT) plus TTRNA-loaded dendritic cell vaccine.
Following surgical resection, biopsy, or cytology examination with confirmatory pathologic diagnosis, patients will be enrolled into Group A (high-dose chemotherapy or HDC) or Group B (non-myeloablative or NMA salvage chemotherapy) based on eligibility for HDC. Patients with localized relapse and have not failed HDC+ peripheral blood stem cell transplant (PBSCT) previously will be enrolled into Group A. Patients with disseminated disease, have previously failed HDC+PBSCT, or are otherwise considered poor candidates for HDC based on overall health status, but otherwise meet eligibility criteria, will be enrolled into Group B. All patients will receive DC + xALT therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Screening:
- Age ≤ 30 years of age.
- Suspected first recurrence/progression of MB/PNET since completion of definitive focal +/- craniospinal irradiation. Disease progression prior to receiving definitive focal +/- craniospinal irradiation will not disqualify patients from enrollment if they have subsequently failed definitive radiotherapy and are at first recurrence/progression at time of enrollment. Patients who are unable to receive radiation therapy due to genetic disorders that put them at significant risk for radiation-induced secondary malignancies (i.e. Gorlin's syndrome or NF1 mutation) are eligible for enrollment at first disease recurrence/progression.
Re-MATCH Protocol:
- Patients must have histologically confirmed recurrent MB/PNET that is a first relapse/progression after completion of definitive radiotherapy +/- craniospinal irradiation. Patients with a first relapse/progression who are unable to receive radiation therapy due to genetic disorders that put them at significant risk for radiation-induced secondary malignancies (ie. Gorlin's syndrome or NF1 mutation) are eligible for enrollment.
- Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration.
- Karnofsky Performance Status of ≥ 50% or Lansky Performance Score of ≥ 50.
- Absolute Neutrophil Count (ANC) ≥ 1000/µl (unsupported).
- Platelets ≥ 100,000/µl (unsupported).
- Hemoglobin > 8 g/dL (may be supported).
- Serum creatinine ≤ upper limit of institutional normal
- Bilirubin ≤ 1.5 times upper limit of normal for age.
- Serum Glutamic Oxaloacetic Transaminase (ALT) ≤ 3 times institutional upper limit of normal for age.
- Serum Glutamic Oxaloacetic Transaminase (AST) ≤ 3 times institutional upper limit of normal for age.
- Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.
- Patient or patient guardian consent to peripheral blood stem cell (PBSC) and/or bone marrow harvest following registration if PBSC or bone marrow (CD34 count of at least 2x10^6/kg) has not been previously stored and available for use.
- Signed informed consent according to institutional guidelines must be obtained prior to registration.
Exclusion Criteria:
- Pregnant or need to breast feed during the study period.
- Active infection requiring treatment or an unexplained febrile (> 101.5F) illness.
- Known immunosuppressive disease, human immunodeficiency virus infection, or carriers of Hepatitis B or Hepatitis C virus.
- Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease.
- Patients receiving concomitant immunosuppressive agents for medical condition.
- Patients who need definitive radiotherapy for treatment of recurrent MB/PNET. Focal boost radiotherapy may be delivered prior to immunotherapy if required for local control.
- Patients receiving any other concurrent anticancer or investigational drug therapy.
- Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
- Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
High dose chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.
|
TTRNA-xALT 3 x 10^7/kg by intravenous injection once.
TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
|
Experimental: Group B
NMA Salvage chemotherapy plus peripheral blood stem cell transplant followed by TTRNA-xALT and TTRNA-DCs.
|
TTRNA-xALT 3 x 10^7/kg by intravenous injection once.
TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12 Month Progression-free Survival (PFS-12)
Time Frame: up to 12 months
|
PFS is defined as time interval from date of first DC vaccine to date of progression (death is also treated as progression) or censoring, whichever happens first.
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Radiographic Response Rate
Time Frame: best overall radiographic response through duration on study (up to 60 months)
|
Radiographic response will be assessed as a percentage change in tumor size from pre-treatment (baseline) MRI scans of the brain and spine obtained with and without contrast.
Evaluation will be based on the NCI-endorsed, World Health Organization RECIST criteria and using a modified version of the MacDonald criteria (complete response, partial response, stable disease, progressive disease or not assessible).
|
best overall radiographic response through duration on study (up to 60 months)
|
Correlate Magnitude and Persistence of Anti-tumor Humoral or Cellular Immunity With Clinical Outcome
Time Frame: baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)
|
Peripheral blood will be used to compare pre-therapy lymphocyte function to defined intervals after each immunization.
Blood will be obtained for immunologic monitoring prior to non-mobilized leukapheresis, prior to immunotherapy, 1 day post Vaccine #1, 4 (+/- 1) days post Vaccine #1, weekly post Vaccine #1 for six weeks.
|
baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)
|
Evaluate Changes in Cytokine Profile and Toll-Like Receptor Activation Status
Time Frame: baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)
|
We will measure serum cytokines pre and post therapy.
Blood will be obtained for immunologic monitoring prior to non-mobilized leukapheresis, prior to immunotherapy, 1 day post Vaccine #1, 4 (+/- 1) days post Vaccine #1, weekly post Vaccine #1 for six weeks.
|
baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)
|
Characterize Immunologic Phenotype of Lymphocyte Subsets and NK Cells
Time Frame: baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)
|
We will conduct flow cytometry from patient samples.
Blood will be obtained for immunologic monitoring prior to non-mobilized leukapheresis, prior to immunotherapy, 1 day post Vaccine #1, 4 (+/- 1) days post Vaccine #1, weekly post Vaccine #1 for six weeks.
|
baseline compared to 6 weeks post vaccine #1 and longitudinal measures through overall survival (up to 60 months)
|
Determine of Overall Survival Rate
Time Frame: up to 60 months
|
Kaplan-Meier estimator will be used to describe length of overall survival from initiation of vaccine #1 for both Groups A and B.
|
up to 60 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Duane Mitchell, MD, PhD, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB201500502
- W81XWH-10-1-0089 (Other Grant/Funding Number: Department of Defense)
- CDMRP-PRO93877 (Other Identifier: Department of Defense)
- OCR13166 (Other Identifier: University of Florida)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Medulloblastoma
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingUntreated Childhood MedulloblastomaUnited States, Canada, Australia, New Zealand, Switzerland, Netherlands
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Ependymoma | Recurrent MedulloblastomaUnited States
-
University of California, San FranciscoWashington University School of Medicine; University of Washington; Pacific Pediatric... and other collaboratorsRecruitingMedulloblastoma | Medulloblastoma, Childhood | Medulloblastoma RecurrentUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...CompletedMedulloblastoma Recurrent | Atypical Teratoid/Rhabdoid Tumor | Medulloblastoma, Childhood, RecurrentUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingMedulloblastoma | Anaplastic MedulloblastomaUnited States, Canada, Puerto Rico, Australia, Netherlands
-
St. Jude Children's Research HospitalSt. Baldrick's FoundationCompletedMedulloblastomaUnited States
-
Xinhua Hospital, Shanghai Jiao Tong University...Children's Neuro-Oncology Group (CNOG)UnknownMedulloblastoma, ChildhoodChina
-
St. Jude Children's Research HospitalEli Lilly and CompanyActive, not recruitingBrain Cancer | Brain Tumor | Medulloblastoma | Brain Tumor, Recurrent | CNS Tumor | Medulloblastoma Recurrent | CNS Cancer | Medulloblastoma, Non-WNT/Non-SHH | Brain Tumor, Pediatric | CNS Neoplasm | Brain Tumor, Refractory | Medulloblastoma, Non-WNT/Non-SHH, Group 3 | Medulloblastoma, Non-WNT/Non-SHH, Group 4United States
Clinical Trials on TTRNA-xALT
-
University of FloridaBeat Childhood Cancer Research ConsortiumRecruitingNeuroblastoma | Diffuse Intrinsic Pontine GliomaUnited States
-
University of FloridaOligo Nation, IncNot yet recruitingRecurrent Oligodendroglioma | Progressive OligodendrogliomaUnited States
-
University of FloridaNational Cancer Institute (NCI); National Institutes of Health (NIH); National... and other collaboratorsActive, not recruitingHigh Grade Glioma | Malignant GliomaUnited States
-
University of FloridaAccelerate Brain Cancer Cure; Lyla Nsouli FoundationActive, not recruitingBrain Stem Glioma | Diffuse Intrinsic Pontine Glioma (DIPG)United States